Humulin N (Insulin Human (Rdna))

Humulin N is used as part of a comprehensive diabetes management plan to provide basal insulin coverage.

• Control fasting plasma glucose levels in patients with type 1 diabetes.
• Maintain basal insulin requirements in adults with type 2 diabetes who need supplemental insulin.
• Combine with rapid‑acting insulin analogues for a basal‑bolus regimen.
• Adjust dosing during periods of illness, stress, or changes in physical activity.
• Facilitate transition from other intermediate‑acting insulins when appropriate.
• Provide basal insulin support in pediatric patients with type 1 diabetes when a stable glucose profile is required.

• Humulin N contains recombinant human insulin that binds to the insulin receptor on target cells, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling cascades, including the PI3‑K/Akt pathway, which promotes translocation of GLUT‑4 transporters to the cell membrane, enhancing glucose uptake in muscle and adipose tissue. Simultaneously, hepatic gluconeogenesis and glycogenolysis are suppressed, reducing endogenous glucose production.

Like all insulin preparations, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, tremor, hunger, or confusion.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, including localized lipoatrophy or lipohypertrophy.
• Weight gain due to increased glucose storage.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or fluid retention, potentially worsening heart failure.
• Hypersensitivity with fever, chills, or systemic symptoms.

When prescribing Humulin N, clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Adjust doses during pregnancy, lactation, or in the elderly due to variable insulin sensitivity.
• Avoid use in patients with known hypersensitivity to recombinant human insulin.
• Monitor for signs of lipodystrophy and rotate injection sites regularly.
• Consider cardiovascular status, as fluid retention can exacerbate heart failure.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin N can interact with other agents, affecting glucose control or insulin action.

Avoid

• Concurrent use of other intermediate‑acting insulins without dose adjustment.
• Combination with high‑dose sulfonylureas, which may precipitate severe hypoglycemia.
• Co‑administration with glucagon antagonists that blunt counter‑regulatory responses.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; monitor glucose closely.
• Corticosteroids can increase insulin resistance, requiring dose escalation.
• Thiazide diuretics may raise blood glucose levels.
• Alcohol intake can cause delayed hypoglycemia; advise moderation.